Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today? ↗
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials. 
Via InvestorPlace
News headline image
Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease ↗
Prometheus Biosciences made waves Wednesday in irritable bowel disease. 
Via Investor's Business Daily
News headline image
These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday ↗
Even as broader markets fell, these companies announced great news. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies ↗
 
Via Benzinga
News headline image
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
From Prometheus Biosciences
Via GlobeNewswire
News headline image
Why Shares of Prometheus Biosciences Slumped This Week ↗
The company's lead pipeline candidate is facing competition from a Pfizer-backed drug. 
Via The Motley Fool
News headline image
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
News headline image
Prometheus Biosciences to Participate at November Healthcare Conferences
From Prometheus Biosciences
Via GlobeNewswire
News headline image
Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know ↗
Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down... 
Via Benzinga
News headline image
Where Prometheus Biosciences Stands With Analysts ↗
Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Expert Ratings for Prometheus Biosciences ↗
Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Analyst Ratings for Prometheus Biosciences ↗
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: 
Via Benzinga
News headline image
Analyst Ratings for Prometheus Biosciences ↗
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: 
Via Benzinga
News headline image
Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday ↗
Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close... 
Via Benzinga
News headline image
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
From Prometheus Biosciences
Via GlobeNewswire
News headline image
7 Top-Rated Biotech Stocks to Buy for Q4 ↗
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
News headline image
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
News headline image
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers ↗
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. 
Via Benzinga
News headline image
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday ↗
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to... 
Via Benzinga
News headline image
Where Prometheus Biosciences Stands With Analysts ↗
  Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Recap of Monday's Biotech Catalysts - End of the Day Summary ↗
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Prometheus Biosciences Stock Shows Rising Relative Strength ↗
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022 ↗
 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
Keybanc cut the price target on Asana, Inc. (NYSE: ASAN) from $97 to $61. Asana shares fell 23.6% to $37.29 in pre-market trading. 
Via Benzinga
News headline image
Analyst Ratings For Prometheus Biosciences ↗
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Expert Ratings For Prometheus Biosciences ↗
Over the past 3 months, 6 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
News headline image
52 Biggest Movers From Friday ↗
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021 ↗
Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.